# PTC Therapeutics, Inc. (PTCT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PTCT
## Company Profile
- Ticker: PTCT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Rare Disease
## Stock Data
- Close: 59.92 USD
- Market cap: 5659633331.740001 USD
- Last updated: 2026-10-13
## Business Overview
### Rare-Disease Medicines
PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases.
### Commercial Portfolio
Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise. PTC also markets additional rare-disease products in multiple regions.
### Vatiquinone
Vatiquinone is an oral small molecule being advanced through a registration study for a rare neurologic disorder following regulatory feedback.
### Votoplam
Votoplam is an oral small-molecule splicing modifier under long-term evaluation in Huntington's disease through a collaboration with Novartis.
## Why The Stock Is Moving

As of Oct 13, 2026, PTCT closed down 4.77% at $59.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of an open-label registration study of vatiquinone in the third quarter of 2026.

## Recent News
- 2026-09-25 20:30 EST — [PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-21999412) — Source: PTC Therapeutics, Inc.
- 2026-09-21 20:30 EST — [PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy](https://biopharmsignal.com/news/PTCT/ptc-completes-acquisition-of-st-920-fabry-disease-gene-therapy-58855184) — Source: PTC Therapeutics, Inc.
- 2026-08-27 12:00 EST — [PTC Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-participate-in-upcoming-investor-conferences-2b92519f) — Source: PTC Therapeutics, Inc.
- 2026-08-24 12:00 EST — [PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-announces-new-sephience-sepiapterin-data-reinforcing-broad-pati-96499003) — Source: PTC Therapeutics, Inc.
- 2026-08-12 20:01 EST — [PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program](https://biopharmsignal.com/news/PTCT/ptc-to-expand-rare-disease-portfolio-with-acquisition-of-bla-stage-st-920-fabry--6adacbb6) — Source: PTC Therapeutics, Inc.